On 13 October 2020, Johnson & Johnson released its 3Q2020 results. Revenue of USD21.08bn beat expectations by 4.3%, and grew by 1.7% (3Q2019: USD20.72bn). Adjusted earnings per share grew by 3.8% to USD2.20 (3Q2019: USD2.12), which beat the USD1.98 expected by the 15 analysts covering Johnson & Johnson.
Pharmaceutical sales increased by 5% for 3Q2020, and generated revenue of USD11.5bn. This segment is in the process of testing and developing a Covid-19 vaccine. Johnson & Johnson reported continued growth across its Oncology (+12.4%) and Immunology (+1.9%) portfolios.
Click here to download the full PDF report.